“Gov. Mike DeWine…called President Trump over the weekend to ask a favor…Trump called up FDA Commissioner Stephen Hahn. ‘And within a very short period of time…they got the approval.’”

Report: “White House pressures FDA on unproven Japanese drug”

Report: “Rudy Giuliani wants FDA to fast-track a stem cell therapy for Covid-19; critics see political meddling”

Flashback: “FDA authorizes widespread use of unproven drugs…” following pressure from Trump.

Washington, DC – Today, Patients Over Pharma called for U.S Food and Drug Administration (FDA) Commissioner Stephen Hahn to resist mounting inappropriate pressure and commit to putting patients and public health first. This follows a recent spate of reports of White House pressure influencing FDA public health decisions as well as the highly-criticized decision to give Gilead Sciences ‘orphan drug’ status for their experimental coronavirus treatment.

“Especially now, as the Trump Administration’s disastrous bungling and downplaying of COVID-19 has put millions of Americans at risk, FDA decisions must be guided by science and done in the best interests of patients, not inappropriate pressure or pharmaceutical industry profits,” said Eli Zupnick, spokesman for Patients Over Pharma.

“Commissioner Hahn has so far been unwilling or unable to resist inappropriate pressure from President Trump or stop the pharmaceutical industry from gaming the system on potential coronavirus treatments – and he needs to reverse course and commit to putting patients and public health first.” 

back to top